25 . 08 .2022
Press release
Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio
22 . 06 .2022
Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)
31 . 05 .2022
Press release
Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022
04 . 04 .2022
Press release
Galderma launches a virtual experience this Rosacea Awareness Month showcasing how the condition goes beyond the visible with Rosacea Space
28 . 03 .2022
Press release
Galderma to present new clinical data and high patient satisfaction across their portfolio of dermal fillers, collagen biostimulators and liquid neuromodulators at AMWC 2022
25 . 03 .2022
Press release
Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting